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Abstract 9 
Microencapsulation of drugs into preformed polymers is commonly achieved through solvent 10 
evaporation techniques or spray drying. We compared these encapsulation methods in terms of 11 
controlled drug release properties of the prepared microparticles and investigated the underlying 12 
mechanisms responsible for the “burst release” effect. Using two different pH-responsive polymers 13 
with a dissolution threshold of pH 6 (Eudragit L100 and AQOAT AS-MG), hydrocortisone, a model 14 
hydrophobic drug, was incorporated into microparticles below and above its solubility within the 15 
polymer matrix. Although, spray drying is an attractive approach due to rapid particle production 16 
and relatively low solvent waste, the oil-in-oil microencapsulation method is superior in terms of 17 
controlled drug release properties from the microparticles. Slow solvent evaporation during the oil-18 
in-oil emulsification process allows adequate time for drug and polymer redistribution in the 19 
microparticles and reduces uncontrolled drug burst release. Electron microscopy showed that this 20 
slower manufacturing procedure generated non-porous particles whereas thermal analysis and X-ray 21 
diffractometry showed that drug loading above the solubility limit of the drug in the polymer 22 
generated excess crystalline drug on the surface of the particles.  Raman spectral mapping illustrated 23 
that drug was homogeneously distributed as a solid solution in the particles when loaded below 24 
saturation in the polymer with consequently minimal burst release.   25 
 26 
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1 Introduction 29 
Polymeric microparticles are increasingly used for controlled drug delivery. Preparation of these 30 
microparticles from pre-formed polymers is based on modifications of three basic methods; solvent 31 
extraction/evaporation, phase separation (coacervation) and spray-drying [1]. The emulsification 32 
solvent evaporation approach is a simple and widely applied technique, extensively studied for the 33 
preparation of polylactic acid (PLA) and poly(lactic-co-glycolic) acid (PLGA) microparticles [2,3].  34 
However, this technique uses relatively large amounts of solvents and results in a suspension of 35 
microparticles in the external phase [4-6]. To acquire a dry powder further processing, such as 36 
filtration or lyophilisation, is needed. Another frequent problem encountered using conventional 37 
emulsification methods is drug crystallisation in the external continuous phase [6]. This problem was 38 
overcome in the case of progesterone-loaded polylactide microspheres using a spray drying method, 39 
hot air being the external phase [7].  40 
With regards to controlled-release properties, one of the difficulties often reported for polymeric 41 
microparticles is an initial high drug release from the polymer matrix, known as a “burst release 42 
effect” [5, 8-13]. In an attempt to explain this phenomenon, a number of theories have been suggested.  43 
Wang et al. (2002) related drug release to the density of the produced microparticles suggesting that 44 
denser particles result in lower release rates [11]. Other authors attributed the burst release to high 45 
residual solvent, reduced glass transition temperature, surface drug enrichment or insufficient 46 
encapsulation [13-16]. In fact, it is well established that the distribution of drugs in delivery systems 47 
influences the release characteristics [15]. However, this is often hard to quantify in-situ and detailed 48 
investigations into the mechanisms responsible for the burst release effect in various 49 
microencapsulation methods have not been reported. 50 
This work evaluates microencapsulation methods in terms of optimal controlled-release 51 
characteristics and uses various analytical techniques to investigate the possible underlying 52 
mechanisms causing burst- or controlled-release properties. Two different pH-responsive polymers 53 
with a dissolution threshold of pH 6 (Eudragit L100 and AQOAT AS-MG) were used to encapsulate 54 
hydrocortisone, a model hydrophobic drug, into microparticles below and above its solubility within 55 
the polymer matrix. Varying the drug loading above and below the solubility within the polymer 56 
tests whether drug encapsulation using spray drying is only marginally dependent on the drug’s 57 
affinities to the solvent and polymer used [7]. Raman microscopy was then used to investigate the 58 
spatial distribution of the drug within the produced microparticles which was related to 59 
experimental release profiles. Unlike previous studies which develop pH-responsive microparticles 60 
intended for gastro-intestinal drug delivery, the goal of this work was to develop controlled delivery 61 
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systems which respond to more subtle pH changes, such as those observed in healthy (pH 5.0-5.5) 62 
versus atopic dermatitis skin (6.0-7.0) [17, 18].  63 
2 Materials and methods 64 
2.1 Materials 65 
Hydrocortisone was purchased from Sigma-Aldrich (UK). Eudragit L100 was kindly provided by Röhm 66 
(Germany). Hypromellose acetate succinate (HPMCAS) (AQOAT® AS-MG) was obtained from Shin-67 
Etsu (Tokyo, Japan). Ethanol, dichloromethane (DCM), hexane (laboratory grades) and sorbitan 68 
sesquioleate were obtained from Sigma-Aldrich (UK). Sodium dodecyl sulphate and Liquid Paraffin 69 
BP were purchased from Fisher Scientific (UK). Sodium phosphate dibasic heptahydrate and sodium 70 
phosphate monobasic dehydrate (Sigma-Aldrich, UK) were used in the preparation of the dissolution 71 
media. 72 
2.2 Production of pH-responsive microparticles 73 
2.2.1 Spray drying  74 
Microparticles were produced using a Mini Spray Dryer, Model 290 (Buchi UK Ltd) under constant 75 
operating conditions for different microparticles. The 50:50 w/w ethanol/water polymeric solutions, 76 
with or without the drug, were fed into the machine by a peristaltic pump at 1.5 ml/min (feed rate 77 
5%) and sprayed through a 0.7mm two-fluid nozzle into the drying chamber. The flow of compressed 78 
nitrogen used to atomise the feed solution was 350 L/min. Inlet temperature was set at 70° C with a 79 
corresponding outlet temperature of ~35° C. A flow of heated nitrogen, at 28 m3/hr (aspirator rate 80 
75%), induced rapid evaporation of solvent from the droplets and led to the formation of solid 81 
microparticles which were collected in a high performance cyclone. In all cases the concentration of 82 
the polymer in the feed solution was maintained at 2% w/w (to circumvent changes that can arise 83 
from differences in feed solution viscosity) while varying hydrocortisone loading at 2.5, 10 and 25% 84 
w/w with respect to polymer. 85 
2.2.2 Solvent-evaporation method 86 
Two variations of the solvent evaporation method were investigated in this study using different 87 
external phases, either water (oil in water emulsification) or liquid paraffin (oil in oil emulsification). 88 
For the oil in water microencapsulation method, 10% w/v polymeric organic solutions were 89 
prepared by dissolving the polymer in a mixed solvent of DCM/ ethanol (7:3 v/v). This solution (10 90 
ml) was added to 100 ml of 0.25% w/v hydroxypropyl methylcellulose (HPMC) aqueous phase. 91 
Similarly, with the oil in oil method, 15 ml of 10% w/v polymer ethanolic solution (oil1) was 92 
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emulsified into 100 ml liquid paraffin (oil2) containing 1% w/w of sorbitan sesquioleate as an 93 
emulsifying agent [19].  94 
For both techniques, the emulsion was obtained by stirring (4 cm four-blade propeller) at 1200 rpm 95 
(IKA® Laboratechnik). Solvent removal was achieved by continuous stirring of the emulsion droplets 96 
at 1200 rpm overnight at room temperature to allow solvent evaporation. The solidified 97 
microparticles were then recovered by vacuum filtration (through Whatman filter paper, 0.45 µm 98 
pore size), washed with 200 ml of water in the case of the oil-in-water emulsification or with three 99 
portions of 25ml n-hexane after the oil-in-oil microencapsulation process. This was followed by 100 
vacuum drying for 6 hrs at room temperature.  2.5%, 10% and 25% w/w hydrocortisone-loaded 101 
microparticles were obtained by incorporating the appropriate drug amount to the initial polymeric 102 
solutions.  103 
2.3 Yield and encapsulation efficiency 104 
Microparticle yields were calculated by:   105 
        Equation 1 106 
 107 
Where, Wtotal is the total solids weight used in the initial polymeric solution and Wrecovered is the 108 
weight of recovered microparticles. To calculate drug encapsulation efficiency, amounts of dry 109 
powder samples equivalent to 20 µg/ml theoretical hydrocortisone loading were dissolved in 110 
ethanol for Eudragit L100 microparticles and in pH7 phosphate buffer for AQOAT AS-MG (as this 111 
polymer is insoluble in ethanol). The amount of hydrocortisone encapsulated was determined by UV 112 
spectrophotometry (Jasco V-530 UV-VIS spectrophotometer) at 242 nm (ethanol) or 248 nm (pH 7 113 
phosphate buffer) against calibration curves. The encapsulation efficiency (EE) was calculated as: 114 
                                  Equation 2                     115 
Where, M actual is the actual amount of the drug encapsulated and M theoretical is the theoretical 116 
amount encapsulated, calculated from the amount of drug added during the manufacturing process. 117 
All analyses were performed in triplicate. 118 
2.4 Scanning electron microscopy 119 
Scanning electron microscopy (SEM) was used to examine the shape and surface morphology of the 120 
microparticles. Powder samples were attached to double sided adhesive carbon tabs mounted on an 121 
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SEM support, coated with gold (Edwards Sputter Coater S150B) and assessed with a high vacuum 122 
scanning electron microscope (SEM) (Cambridge 360 stereoscan). The SEM instrument was operated 123 
at an accelerating voltage of 20 KeV and a working distance of about 15 mm. 124 
2.5 Density 125 
Bulk density (bρ) was measured by filling the dry powder into a 2 ml graduated syringe whose 126 
bottom was sealed with Parafilm™ [20, 21]. The weight and volume occupied by the powder was 127 
recorded to calculate bρ. The tap density (tρ) of the powders was then evaluated by tapping the 128 
syringe onto a level surface at a height of about 2 cm [20], until no change in volume was observed. 129 
The resultant volume was then recorded to calculate tρ. Each measurement was performed in 130 
triplicate. 131 
2.6 Thermo-gravimetric Analysis (TGA) 132 
Thermo-gravimetric analysis assessed the residual solvent within the prepared microparticles. These 133 
investigations were performed in a Q50 TA instrument (TA Instruments Ltd, UK) equipped with TA 134 
universal analysis software. Samples of about 10 mg were heated from 30 to 200°C at 20°C /minute 135 
under a nitrogen purge of 50 ml/min using a platinum pan. 136 
2.7 Differential scanning calorimetry (DSC)  137 
Thermal behaviour of polymers, drug, drug free microparticles and drug-loaded microparticles was 138 
analysed using differential scanning calorimetry (Q2000 TA instruments) equipped with TA universal 139 
analysis software. The apparatus was calibrated with indium prior to analysis. Approximately 4 mg 140 
samples were accurately weighed into standard aluminium pans, which were then crimped and 141 
heated from 30 to 150°C at 10°C/minute with a 30 min isothermal hold at 150°C to remove any 142 
excess moisture. The samples were then cooled to 30°C and heated to 250°C at 10°C /minute under 143 
a nitrogen purge of 20ml/min. All samples were tested in triplicate.  144 
2.8 X-ray powder diffraction (XRPD) measurements 145 
X-ray powder diffraction patterns of the starting materials (hydrocortisone and Eudragit L100) and 146 
microparticles were obtained using a Bruker D8 Advance diffractometer (Bruker, Germany), using Cu 147 
Kα radiation (λ= 1.5406 Å). Samples were scanned from 5 to 45° 2θ, with a step size of 0.017° and a 148 
count time of 3 seconds per step. Samples were rotated at 30 rpm during analyses. The generator 149 
was set to 40 keV and 40 mA. 150 
2.9 Raman microscopy 151 
Raman spectra were recorded using a dispersive Renishaw inVia Raman microscope coupled with a 152 
532 nm diode laser source and a Leica DM2500 M microscope. A 100 x working-length objective was 153 
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used for optical imaging and spectral acquisition. The collected radiation was directed through a 154 
notch filter that removes the Rayleigh photons, then through a confocal hole and the entrance slit 155 
onto a grating monochromator (2400 groove/mm) that disperses the light before it reaches the 156 
charge-coupled device (CCD) detector. The spectrograph was set to provide a spectral range of 100-157 
2000 cm-1. 158 
Depth profiling of the oil-in-oil generated microparticles was acquired at a step of 2 µm for the 25% 159 
hydrocortisone-loaded microparticles and a step of 0.8 µm for 10% and 2.5% w/w loaded-160 
microparticles. Spectrum acquisition times were typically 180s. Spectra were collected to a total 161 
depth of 15.20 µm, for the 2.5% and 10% w/w hydrocortisone-loaded microparticles, and 38 µm for 162 
25% hydrocortisone-containing microparticles due to their larger particle diameters. In all cases, a 163 
total of 20 spectra were acquired starting from the microparticle’s surface. 164 
2.10 In vitro dissolution testing 165 
pH-stepped dissolution testing of the different drug-containing microparticles was performed using 166 
USP II apparatus (paddles) (Varian VK7010 dissolution system) at 50 rpm and 32±1oC (which 167 
represents normal skin temperature as the microparticles are intended for topical drug delivery). 168 
The reported aqueous solubility of hydrocortisone is 0.28 mg/ml [18, 22]. Therefore, amounts of drug-169 
containing microparticles equivalent to 0.02 mg/ml hydrocortisone on complete dissolution were 170 
used, ensuring sink conditions (C<0.1 Cs). The powders were first tested in 500 ml of 0.1M pH 5 171 
phosphate buffer for two hours, after which the pH was increased to 7 by the addition of 100 ml  172 
0.29M NaOH, and testing then continued for a further two hours. Samples (1 ml) were withdrawn 173 
periodically, passed through a 0.45 µm membrane filter (Millipore®) and assayed by UV 174 
spectrophotometery at 248 nm, a wavelength at which no interference from the polymers was 175 
observed.  176 
2.11 Statistical analysis 177 
Differences in tap density measurements and maximum drug release between Eudragit L100 178 
microparticles obtained from the two methods (spray drying and solvent evaporation) and 179 
containing different drug-loadings were assessed using one way analysis of variance, (Genstat; 180 
version 12); in all cases p<0.05 denoted significance. 181 
3 Results and discussion 182 
Unlike the solvent evaporation technique, encapsulation using spray drying is thought to be only 183 
slightly dependent on the drug’s compatibility with the solvent and polymer used [7]. In this study, 184 
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the effect of drug:polymer compatibility on hydrocortisone release from the prepared microparticles 185 
was explored by incorporating the drug at levels below and above its solubility limit within the 186 
polymer matrices. The solubility of hydrocortisone in Eudragit L100 and AQOAT AS-MG was found 187 
through microscopic examination of polymer films [23]. A high solubility of the drug in the polymer 188 
matrix is indicative of high drug-polymer compatibility [6, 23] and results in better incorporation of the 189 
drug within the prepared microparticles. Hydrocortisone was found to be more soluble (13-14% 190 
w/w) in Eudragit L100 films [24] compared to AQOAT AS-MG (9-10% w/w; Figure 1).   191 
INSERT Figure 1 192 
Various other parameters including the physicochemical properties of both drug and polymer need 193 
to be considered for successful encapsulation of drugs into polymeric microparticles. The model 194 
drug used, hydrocortisone, has a reported water solubility of 0.28 mg/ml [16], and we previously 195 
reported its solubility in ethanol to be 11.4±0.33 mg/ml [24].  These solubility’s dictate the extent of 196 
drug diffusion to the surface of the microparticles during the preparation process and ultimately 197 
affect drug release. 198 
3.1 Preparation of pH-responsive microparticles 199 
3.1.1 Spray drying as a microencapsulation technique 200 
We previously reported the potential use of spray drying to prepare pH-responsive Eudragit L100 201 
microparticles [24]. The method was optimised in terms of drug release, taking into account the effect 202 
of different solvent systems and various polymer concentrations. Using Eudragit L100 as a pH-203 
responsive polymer, it was found that a polymer content of 2% w/w and a solvent system of 1:1 w/w 204 
ethanol/water led to the lowest drug release at pH 5, a pH at which the polymer is not soluble. Using 205 
these optimised conditions, the effect of varying the drug loading (2.5% and 25% w/w) on the 206 
release profile was investigated [24]. Here, we also report the effect of 10% w/w hydrocortisone-207 
loading (Table 1). AQOAT AS-MG microparticles were also generated using the same conditions to 208 
explore the methods’ transferability to other polymers (Table 1). Encapsulation efficiency was high, 209 
with more that 88% of the drug incorporated in all cases. Morphological characteristics of Eudragit 210 
L100 and AQOAT AS-MG microparticles containing different hydrocortisone loadings were examined 211 
with SEM imaging as shown in Figure 2. The rough morphology of these microparticles is thought to 212 
result from polymer phase separation at the surface of the drying droplets [24]. 213 
INSERT Table 1 214 
INSERT Figure 2 215 
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Powders prepared from AQOAT AS-MG tended to aggregate. The presence of aggregates increases 216 
the voids within the powder bed and results in relatively low tap densities compared with Eudragit 217 
L100 microparticles [24] (Table 1). Further investigation of the pH-responsiveness of these spray dried 218 
microparticles, from pH 5 to 7, demonstrated that AQOAT AS-MG particles dissolve at a lower pH 219 
than expected,  between pH 5.3 and 5.4 (data not shown). Similar observations were reported by 220 
Friesen et al who found AQOAT AS-MG soluble above pH 5.2 [25]. In contrast, Eudragit L100 221 
microparticles dissolved at pH 5.8 to 5.9, close to the reported polymer solubility threshold of pH 6 222 
[24]. Differential scanning calorimetry did not show any changes between the polymer microparticles 223 
and the initial AQOAT AS-MG powder (data not shown). The discrepancy in pH-responsiveness 224 
between the manufacturer information and experimental results for AQOAT AS-MG might be a 225 
result of differences in testing methodologies; the manufacturer’s information is based on 226 
disintegration testing of 1 cm2 polymeric films which may dissolve more slowly than the 227 
microparticles [26].  228 
Due to the relatively high drug burst release observed previously with spray-dried Eudragit L100 229 
microparticles at pH 5 and 1.2 [24], pHs at which the polymer is not soluble, an alternative 230 
microencapsulation technique, namely, the solvent-evaporation method, was investigated. 231 
3.1.2 Oil-in-water emulsification/solvent evaporation technique 232 
In the oil in water emulsification process, the drug and polymer are first dissolved in a water-233 
immiscible solvent, usually dichloromethane (DCM), and the resulting organic phase is emulsified 234 
into an aqueous phase containing an appropriate emulsifier. The organic solvent can then be 235 
removed by evaporation or extraction. The method has been used to prepare Eudragit-based 236 
systems, for the sustained release grades RL and RS [27, 28], which are neutral copolymers of poly 237 
(ethylacrylate, methyl methacrylate) and trimethyl aminoethyl methacrylate chloride [27]. pH-238 
responsive particles have also been successfully prepared using Eudragit P-4135F [29-31]; Eudragit P-239 
4135F is synthesised by the co-polymerisation of methacrylic acid, methyl methacrylate and methyl 240 
acrylate [31] and exhibits a dissolution threshold of pH 7.2 [31].  241 
The above Eudragit grades are all soluble in DCM, which is advantageous as it facilitates the 242 
emulsification of the polymer solution. Moreover, the limited solubility of DCM in water prevents 243 
drug loss to the external aqueous phase which can occur with solvent diffusion. However, Eudragit 244 
L100 is not soluble in DCM whereas AQOAT AS-MG is only partially soluble (swellable) [32]. Therefore, 245 
a mixed solvent of 7:3 v/v DCM/ethanol was used to solubilise the polymers in the initial organic 246 
phase [33-36]; the ethanol content was minimised to limit drug diffusion into the aqueous phase. 247 
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Using the DCM/ethanol cosolvent system, microparticles were successfully prepared using a 10% 248 
w/v AQOAT AS-MG organic solution (Figure 3). The hollow nature of these microparticles is 249 
attributed to rapid ethanol diffusion followed by polymer precipitation [35]. The rate of solvent 250 
diffusion during the initial stage of microparticle preparation is determined by its water solubility. 251 
The aqueous solubility of DCM at 25⁰C is 1.85% [2, 11] whereas ethanol is completely miscible with 252 
water. The partial solubility of AQOAT AS-MG in DCM means that the polymer shell formed at the 253 
interface of the emulsification droplets is non-rigid. This allows for DCM evaporation through 254 
eruptions in the polymeric shell. The net result is the formation of spherical intact microparticles 255 
with a porous surface upon complete shell solidification (e.g. Figure 3, D).  256 
INSERT Figure 3 257 
These morphological observations are consistent with tap density measurements of AQOAT AS-MG 258 
microparticles (Table 2), which are considerably lower than those calculated for the spray dried 259 
powders (Table 1) and are attributed to the hollow nature of the particles. However, hydrocortisone 260 
encapsulation into AQOAT AS-MG microparticles resulted in relatively low encapsulation efficiencies 261 
(Table 2) probably as a result of rapid ethanol flux into the external aqueous phase. A comparable 262 
phenomenon was reported in the literature for the encapsulation of estradiol and indometacin into 263 
Eudragit L100-55 [6].   264 
INSERT Table 2 265 
Although hydrocortisone is a hydrophobic drug, it exhibits an appreciable solubility in aqueous 266 
media of 0.28 mg/ml [16]. The diffusion of ethanol into the external aqueous phase during the 267 
emulsification process leads to drug leaching and increased hydrocortisone solubility in the external 268 
aqueous phase. This phenomenon may explain the low encapsulation efficiency measured and the 269 
appearance of drug crystals in the external aqueous phase at 25% w/w theoretical drug loading 270 
(Figure 3, C). Microparticles prepared at 2.5% w/w drug loading show similar morphological 271 
characteristics to the drug-free microparticles with no visual evidence of drug crystallisation (Figure 272 
3, B). Nonetheless, the encapsulation efficiency of the drug was low despite the fact that it was 273 
incorporated at a level well below its solubility limit within the polymer.  274 
In contrast, at 10% w/w polymer concentration, sticky Eudragit L100 droplets were produced during 275 
the early stages of the oil-in-water emulsification process leading to the formation of elongated 276 
polymeric structures (data not shown). In an attempt to overcome this problem, a reduced polymer 277 
concentration was used to decrease polymer-polymer interactions in the initial polymeric organic 278 
solution which, in turn, reduces the polymer’s tendency for precipitation and enables polymer 279 
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emulsification into the external aqueous phase. Nonetheless, the emulsified droplets generated in 280 
the early stages of particle formation tended to collapse during the solvent evaporation step (Figure 281 
3, E), possibly due to the brittle nature of the Eudragit L100 shell that forms at the interface of the 282 
droplets. The glass transition temperature of Eudragit L100 was reported to be about 160⁰C with a 283 
corresponding minimum film formation temperature (MFT) of 85⁰C [36]. Similarly to AQOAT AS-MG, 284 
the hollow nature of Eudragit L100 microparticles is attributed to rapid ethanol diffusion, polymer 285 
precipitation and subsequent shell formation. 286 
3.2 Oil-in-oil emulsification/solvent evaporation technique 287 
An oil-in-oil emulsification process was adopted to circumvent the problem of drug leakage into the 288 
external phase. Kendall et al have recently developed a reproducible oil-in-oil microencapsulation 289 
method for fabricating Eudragit L100 microparticles intended for gastrointestinal delivery [19]. The 290 
method uses liquid paraffin, a non-solvent for both drug and polymer, as the external oil phase. 291 
Despite the fact that the use of DCM (ICH class 2) was avoided and ethanol (ICH class 1) was chosen 292 
to solubilise the polymer in the internal oil phase, the utilisation of hexane (ICH class 2) for external 293 
oil phase removal is inevitable.  294 
Drug-free Eudragit L100 microparticles prepared from a 10 % w/v polymeric solution using the oil-in-295 
oil emulsification process have a smooth surface and are less polydisperse than microparticles 296 
produced from the spray drying method (Figure 4) with no observed surface porosity. The 297 
solubilisation of 2.5% and 10% w/w hydrocortisone in the initial polymeric solution led to the 298 
formation of spherical microparticles with similar morphological characteristics. At 25% w/w 299 
theoretical drug loading, hydrocortisone was not fully soluble in the initial polymeric solution due to 300 
its limited solubility in ethanol. Therefore, the non-solubilised drug crystals are incorporated into 301 
relatively large microparticles (about 150 µm diameter compared with 30 µm diameter for drug-302 
free, 2.5 and 10% drug-loaded microparticles) (Figure 4). The presence of drug crystals at a relatively 303 
high theoretical loading might have increased the viscosity of the initial polymeric solution. A more 304 
viscous phase will require larger shear stress (stirring in this case) to break the emulsion droplets 305 
into smaller sizes.   306 
INSERT Figure 4 307 
Yield, encapsulation efficiency and tap density results obtained from the emulsification of 10% w/v 308 
polymeric solutions into liquid paraffin are presented in Table 3. The encapsulation efficiencies 309 
obtained for hydrocortisone are relatively high, comparable to those calculated for the spray dried 310 
powders (Table 1). The lower encapsulation efficiency at 25% w/w theoretical drug loading can be 311 
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explained by the loss of uncoated drug crystals into the external oil phase. The high tap density 312 
measurements obtained for the oil in oil microparticles suggest that they are solid. However, the oil-313 
in-oil generated Eudragit L100 microparticles with 25% hydrocortisone-loading presents a low tap 314 
density due to the presence of crystals within the microparticles which might have disturbed their 315 
internal structure and led to pore formation (Figure 4, D).  316 
INSERT Table 3 317 
The relatively high polymer concentration (10 % w/v), used in the internal oily phase, increased 318 
polymer viscosity and caused rapid droplet solidification [2]. The rapid solidification of microparticles 319 
is advantageous in achieving high drug encapsulation efficiency as it hinders drug migration to the 320 
particles’ surface [2]. In fact, a 1% w/v Eudragit L100 concentration led to inefficient hydrocortisone 321 
encapsulation with apparent drug crystals in the external phase and on the surface of the dried 322 
microparticles (data not shown). In this case, the low polymer viscosity and slow droplet 323 
solidification allowed more time for drug loss through diffusion.  324 
The transferability of the oil-in-oil microencapsulation method to different grades of Eudragit; L100, 325 
S100 and L55, has been reported by Kendal et al. [19]. Nonetheless, its applicability to structurally 326 
non-related polymers has not been investigated. Here, the oil-in-oil emulsification method was used 327 
to prepare AQOAT AS-MG microparticles but the initial oil phase was substituted by a 7:3 v/v 328 
DCM/ethanol co-solvent system to allow for AQOAT solubilisation. SEM images of the obtained 329 
microparticles show similar morphological characteristics to Eudragit L100 particles but with a 330 
rougher surface topography (Figure 4, E and F).  331 
Unlike the oil-in-water emulsification method, the microparticles obtained from the oil-in-oil 332 
microencapsulation process appear to be solid. This can be attributed to the relatively slow “good 333 
solvent” (ethanol) removal rate. This allows time for polymer redistribution within the drying 334 
droplets and results in the formation of solid microparticles. Even when a mixed solvent of 335 
DCM/ethanol is used, as for AQOAT AS-MG, the morphology of the particles obtained is similar to 336 
that for Eudragit using ethanol alone.   337 
3.3 Drug release 338 
From the different microencapsulation techniques tested, spray drying and the oil-in-oil 339 
microencapsulation method resulted in the successful formation of microparticles with efficient drug 340 
encapsulation. Dissolution data of these powders are in Figure 5, showing stepped dissolution of 341 
microparticles below and above the pH solubility of the polymer. Although the size of the 342 
microparticles can influence the rate of drug release in the initial stages, here we compare total drug 343 
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release after 2 hours at pH 5, when a plateau is reached. Total drug release at this stage is more 344 
likely to be due to other factors such as particles porosity or drug distribution. In fact, a study that 345 
investigated the release 5-fluorouracil-loaded PLGA-based microparticles has showed that 346 
underlying drug release mechanisms were independent of the microparticle size [37]. Although the 347 
different size fractions released the drug at different rates initially, they all reached the same level of 348 
relative drug release after 21 days [37]. 349 
INSERT Figure 5 350 
With both preparation methods, Eudragit L100 microparticles showed better controlled release 351 
properties than AQOAT AS-MG microparticles, i.e. lower relative drug release after 2 hours at pH 5. 352 
At 2.5% and 10% w/w hydrocortisone-loading, Eudragit L100 microparticles obtained from the oil-in-353 
oil encapsulation technique led to negligible hydrocortisone release at pH 5 (Figure 5, B). At 25% 354 
w/w drug loading, due to the limited solubility of hydrocortisone in ethanol (11.4±0.33 mg/ml), 355 
about 50% of the drug was not dissolved in the initial polymeric solution. During the emulsification 356 
process, the non-dissolved drug crystals preferentially distribute on the particles’ surface (Figure 4, 357 
D) resulting in about 40% drug burst release at pH 5 after 2 hours (Figure 5, B). This suggests that the 358 
remaining 10% of undissolved drug crystals is incorporated deeper into the polymer matrix. In 359 
contrast, regardless of the drug loading level, the spray dried powders showed a high burst release 360 
effect at pH 5, a pH at which the polymer is not soluble (Figure 5, A).  361 
These variations in drug release can be attributed to differences in microparticle formation during 362 
manufacture. The burst release observed from the spray-dried microparticles implies that they are 363 
porous; the presence of pores within microparticles leads to rapid water penetration inside the 364 
particles and subsequent rapid diffusion of the encapsulated drug. The process of pore formation 365 
during spray drying arises from phase separation during the encapsulation process and subsequent 366 
drug partitioning between polymer-poor and rich regions within the drying droplet [24]. This 367 
phenomenon results in some drug entrapped within the polymer-poor region which dries to form 368 
pores or less supported structures [11].  369 
Interestingly, the spray dried microparticles containing hydrocortisone below the solubility limit 370 
within the polymer (2.5 and 10% w/w) provided lower burst release than at 25% w/w loading (Figure 371 
5, A). Spray drying below the solubility limit of the drug might lead to higher drug content in the 372 
polymer-rich regions of the dried particles and possibly better controlled release properties. 373 
Nonetheless, at 2.5% and 10% w/w hydrocortisone loading, the burst release at pH 5 was only 374 
reduced by about 10% at 2 hours compared to that when the drug exceeded its solubility at 25% 375 
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w/w load. This implies that either; a) drug partitioning to polymer-poor regions was still 376 
predominant or b) drug enrichment at the surface was also accounting for the drug burst release. As 377 
the evaporating droplet shrinks, its receding droplet surface leads to increased solute concentration 378 
at the surface and subsequent diffusional flux to the centre [38]. During the spray drying process, high 379 
solvent evaporation rates can lead to rapid droplet shrinking which does not allow time for drug 380 
redistribution and results in surface drug enrichment [14]. 381 
On the other hand, with the oil-in-oil microencapsulation process, solvent evaporation occurs more 382 
slowly as the emulsified droplets are stirred overnight at room temperature to allow for complete 383 
solvent evaporation. The relatively long evaporation time during the oil-in-oil microencapsulation 384 
process, compared with the fast solvent evaporation during spray drying, allows adequate time for 385 
both drug and polymer redistribution and diffusion to the centre of the emulsified droplets which 386 
may result in better controlled release characteristics. Moreover, the long evaporation time is less 387 
likely to produce porous microparticles. In comparison to Eudragit L100 microparticles, 388 
hydrocortisone-loaded AQOAT AS-MG particles resulted in a significantly higher drug release at pH 5 389 
(Figure 5, C & D) despite the fact that the drug was incorporated at 2.5% w/w, a level well below the 390 
solubility limit of hydrocortisone within the polymer matrix. This can be attributed to differences in 391 
the internal phase solvent system. The use of a DCM/ethanol co-solvent system may lead to a more 392 
porous structure due to the relatively fast evaporation of DCM and might explain the lower tap 393 
density measurements obtained for AQOAT AS-MG microparticles (Table 2). 394 
It is notable that the rate of drug release from the oil in oil microparticles at pH 7 (Figure 5, B, post 395 
120 mins) increases with drug loading. This effect may reflect drug distribution within the polymer 396 
matrix; the more drug available at or near the surface of the particle the more rapid is the initial 397 
release since less polymer is available to hinder drug diffusion. Using the same oil in oil 398 
microencapsulation method, Nilkumhang et al. investigated partitioning of fluorescent dyes 399 
between the internal (ethanol) and external (liquid paraffin) phases and found a correlation between 400 
the partition coefficient and molecular distribution within the prepared microparticles [39]. However, 401 
in this study, the same drug is used and the partition coefficient between ethanol and liquid paraffin 402 
is therefore constant.  403 
3.4 Mechanisms of “burst release” 404 
3.4.1 Particle density and percentage porosity 405 
Wang and Wang (2002) suggested that the density of the produced microparticles could profoundly 406 
influence drug release since increased particulate density can restrict the diffusion of the drug from 407 
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the microparticles [11]. Tap density measurements can offer insight into this phenomenon; assuming 408 
perfect packing of the tapped powder and a monodisperse size distribution, tap density values are 409 
approximately a 21% underestimate of particle density [40].  Although this method may not fully 410 
discriminate between subtle structural differences due to possible electrostatic interactions, 411 
especially when dealing with small particles, it has previously been useful employed to study 412 
microparticles[20]  and the data supports that from our SEM imaging and Raman microscopy 413 
investigations. 414 
Tap density measurements of the spray dried and oil-in-oil microparticles are reported in Table 1 415 
and 3 respectively. For both polymers loaded with drug below the solubility limit (2.5% and 10% 416 
w/w), the oil-in-oil microparticles displayed significantly higher tap densities than the spray dried 417 
particles. This correlates with in-vitro release testing as the more dense oil-in-oil Eudragit particles 418 
showed negligible drug release at pH 5 (Figure 5, B) compared with the less dense spray dried 419 
particles of the same polymer (Figure 5, A).  Likewise, the oil-in-oil generated AQOAT particles gave 420 
lower burst release at pH 5 than the equivalent spray dried material.  Thus, for both polymers, 421 
significant burst release correlated with lower tap densities.  422 
In contrast, microparticles prepared from the oil/oil method at 25% w/w drug-loading showed a 423 
significantly lower tap density measurement than other Eudragit L100 microparticles (Table 3) 424 
suggesting a higher level of intraparticulate voids (p<0.05). This increased porosity might be due to 425 
the presence of drug crystals in the initial polymeric solution which might have disturbed the flow of 426 
the polymer within the emulsification droplets leading to the formation of pores. Moreover, drug 427 
crystals are more likely to accumulate at the polymer/liquid paraffin interface during droplet drying 428 
and surface recession.  Eudragit S100 microparticles containing 50% and 66.7% w/w prednisolone 429 
were hollow and showed an extensive amount of crystalline drug on the surface [41]. As expected, 430 
these morphological changes were also attributed to a high burst release [41].  Similarly, Yadav et al. 431 
(2009) [42] showed that increased intraparticle porosity of carbamazepine in Eudragit RSPO was due 432 
to low polymer deposition in the empty spaces between the agglomerated microcrystals. Increased 433 
drug deposition at the surface of our microparticles coupled with increased intraparticulate porosity 434 
explains the relatively high burst release of hydrocortisone from 25% w/w drug-loaded 435 
microparticles produced from the oil in oil emulsification method (Figure 5, B). 436 
3.4.2 Residual solvent level 437 
Burst release of rifampicin from poly(D, L-lactic acid) (PDLLA)/ Resomer (30:70) spray dried 438 
microparticles was attributed to residual solvent reducing the glass transition temperature (Tg) of 439 
the polymer, leading to accelerated water uptake and greater drug diffusion from the microparticles 440 
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[13].  The residual solvent in the microparticles prepared from the oil-in-oil and spray drying methods 441 
at different drug loadings was determined using thermo-gravimetric analysis (Table 4). No significant 442 
differences (P>0.05) were seen between the two methods of manufacture or between various drug 443 
loadings, showing that, for these particles, residual solvent effects were not responsible for burst 444 
effects. It should be noted that residual paraffin from the oil in oil method is not detected by this 445 
technique. However, paraffin is a hydrophobic non-solvent for the polymer and therefore is not 446 
expected to increase water uptake or influence drug release. 447 
INSERT Table 4 448 
3.4.3 Drug crystallinity 449 
Differential scanning calorimetry and X-ray analysis of Eudragit L100, hydrocortisone, drug-free 450 
microparticles and hydrocortisone-loaded microparticles were used to identify changes in drug form 451 
that might have occurred during the encapsulation process (Figures 6 and 7). Drug encapsulation 452 
within microparticles depends on its initial state in the polymeric solution and on the preparation 453 
process [43]. Differential scanning calorimetry of untreated Eudragit L100 shows a broad phase 454 
transition between 180 and 235˚C (Figure 6). The nature of this phase transition is still unclear, but 455 
dissociation of inter-molecular hydrogen bonds and anhydride formation has been suggested [44]. 456 
The DSC curve of hydrocortisone powder show an endothermic melting peak at 222±0.7˚C (Figure 6), 457 
in accordance with the literature value of 221±2 °C [45]. 458 
INSERT Figure 6 459 
INSERT Figure 7 460 
Drug-free, 2.5% and 10% w/w hydrocortisone-loaded Eudragit L100 microparticles prepared from 461 
the oil-in-oil microencapsulation method did not show any additional phase transitions to those 462 
already observed in the untreated Eudragit powder. This suggests that, at 2.5% and 10% 463 
hydrocortisone loading, the drug is soluble in the Eudragit L100 polymer matrix giving rise to a solid 464 
solution.  For 25% hydrocortisone-loaded microparticles, where a proportion of the drug was 465 
incorporated in its crystalline form, a small endothermic peak at around 200˚C corresponding to 466 
melting point depressed hydrocortisone crystals was observed. X-ray analysis of these samples 467 
(Figure 7) supports the DSC data with no crystalline drug found at low loadings but excess drug (at 468 
25% w/w loading) was present in the same crystalline form as the starting material. 469 
However, for spray dried materials, hydrocortisone-loaded Eudragit L100 microparticles show an 470 
endothermic shoulder which moves to a lower temperature as the drug loading increases (Figure 6). 471 
However, as the polymer also shows an endothermic peak in the same region, it was unclear 472 
16 
 
whether this thermal feature was due to the presence of drug crystals.  From the X-ray diffraction 473 
patterns of unprocessed drug and hydrocortisone-loaded microparticles, the intense crystalline 474 
peaks at  14.5 and 17 degrees 2θ, observed for unprocessed hydrocortisone, were absent in the 475 
diffractogram of drug-containing spray dried microparticles (Figure 7). This suggests that the drug is 476 
present in an amorphous form within the spray dried microparticles. The presence of amorphous 477 
drug, coupled with the small size of spray dried microparticles may facilitate drug release and can 478 
partly explain the relatively high burst release observed for this material (Figure 5, A). However, the 479 
fact that the drug is non-crystalline at 2.5% and 10% w/w within Eudragit L100 microparticles 480 
produced from the oil-in-oil microencapsulation method suggests that this phenomenon is not solely 481 
responsible for the non-controlled burst effect; a further potential mechanism is the relatively high 482 
drug enrichment at the surface of the spray dried microparticles compared with the oil-in-oil 483 
powders. 484 
3.4.4 Drug distribution within the microparticles 485 
In order to clarify whether release from the microparticles relates to the spatial distribution of the 486 
drug within the polymer matrix, confocal Raman microscopy was used for depth profiling Eudragit 487 
L100 microparticles [46]. As discussed above, the evaporation of ethanol during microencapsulation 488 
can result in drug migration to the microparticle’s surface resulting in surface drug enrichment which 489 
can result in a higher or more rapid drug release.  490 
Figure 8 shows the Raman spectra of hydrocortisone and Eudragit L100 powders used for 491 
microparticle production. Hydrocortisone has characteristic Raman bands at 1643 and 1610 cm-1 492 
which are consistent with C=C stretching modes at the 4-5 position [47, 48] (Figure 8). On the other 493 
hand, Eudragit L100 shows distinctive Raman peaks at 1751 and 1451 cm-1 which are assigned to the 494 
C=O stretching and –CH2- scissoring modes respectively 
[48]. The Raman spectrum of this polymer 495 
also displays relatively strong peaks at 1205, 1120, 969 and 812 cm-1 which are associated with C-H 496 
and C-C wagging vibrations [48].   497 
Insert Figure 8 498 
Raman depth profiling of Eudragit L100 microparticles at 25% w/w drug-loading is shown in Figure 9, 499 
A (data not shown for 2.5% and 10% w/w drug-loading). Based on the linear relationship between 500 
the intensity of the peak from the measured analyte and its concentration [49], the depth profiles 501 
were processed to acquire component graphs detailing the proportion of both hydrocortisone and 502 
Eudragit L100 as a function of depth (Figure 9, C, D and E). At 25% w/w drug-loading, the intensities 503 
of the characteristic hydrocortisone peaks at 1643 and 1610 cm-1 were variable: they increased 504 
dramatically at a depth of 12 µm then declined (Figure 9, A). This high intensity region coincides with 505 
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the presence of a drug crystal inside the microparticle as illustrated in the SEM image of a 506 
microtomed 25% w/w hydrocortisone-loaded particle where drug crystals can be seen both on the 507 
surface and within the polymer matrix (Figure 9, B). It should also be noted that this SEM image 508 
supports tap density measurements obtained for the 25% w/w drug-loaded microparticles (Table 3). 509 
The considerably lower tap density measurement of these microparticles (Table 3) compared to 510 
other powders containing lower amounts of drug is due to a higher level of intraparticulate voids. 511 
SEM images of the internal structure of 2.5% and 10% w/w hydrocortisone-containing microparticles 512 
showed no evidence of crystal inclusions. 513 
Insert Figure 9 514 
In the case of 2.5% and 10% w/w hydrocortisone-loading, the proportion of both hydrocortisone and 515 
Eudragit L100 remained constant throughout the depth studied (Figure 9, D and E).  Assuming that 516 
these microparticles have a monodisperse size of about 30 µm (Figure 4), these results show that the 517 
concentration of hydrocortisone at the surface and the core (15.20 µm) is the same, i.e. the oil-in-oil 518 
microencapsulation process did not result in drug enrichment on the surface.   In contrast, with 25% 519 
w/w hydrocortisone-loading, the proportion of hydrocortisone relative to Eudragit L100 varied 520 
depending on the presence of drug crystals within the polymer matrix (Figure 9. C). These results 521 
support SEM images and XRPD/DSC data, with regions within the particle showing increased 522 
intensities of hydrocortisone characteristic bands showing the presence of drug crystals. It should be 523 
noted that the data presented in Figure 9 is representative of three different microparticles selected 524 
randomly for each drug loading. Unfortunately, depth profiling of the spray dried microparticles for 525 
comparative purposes was not possible due to their small particle size (size range 1-5 µm, Figure 2). 526 
Since Raman depth profiling of the oil-in-oil microparticles demonstrated that, at 2.5% and 10% w/w 527 
drug-loading, no differences in the spatial distribution of hydrocortisone existed within the polymer 528 
matrix, variations in drug release at pH 7 can be solely due to differences in the polymer/drug ratio. 529 
In other words, an increase in the proportion of Eudragit L100 relative to hydrocortisone, e.g. at 530 
2.5% drug-loading, leads to a moderately slower drug release as a larger amount of polymer is 531 
available to hinder drug diffusion.   532 
4 Conclusion 533 
Of the different microencapsulation techniques tested, spray drying and the oil-in-oil emulsification 534 
method successfully formed microparticles with high levels of drug encapsulation. Scanning electron 535 
microscopy and dissolution testing revealed that the microparticles prepared from the oil-in-oil 536 
encapsulation method had more favourable morphological and release characteristics. In fact, the 537 
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encapsulation of hydrocortisone at levels below its saturation solubility within Eudragit L100; 2.5 and 538 
10% w/w, lead to negligible release at pH 5, a pH at which the polymer is not soluble, whereas 539 
increasing the pH to 7 resulted in near instantaneous drug release. The spray dried powders, on the 540 
other hand, showed high drug burst release at pH 5. These variations in drug release are partially 541 
attributed to differences in microparticle formation. In contrast with the spray drying process, slow 542 
solvent evaporation and droplet solidification during the oil-in-oil emulsification process allows 543 
adequate time for drug and polymer redistribution which may result in denser microparticles and 544 
better controlled release characteristics. Tap density measurements showed good correlation with 545 
in-vitro drug release testing and SEM imaging, especially for the oil-in-oil produced microparticles, 546 
with high density particles showing better controlled release properties.  Thermal, X-ray and 547 
confocal Raman analysis of the particles also demonstrates the importance of drug loading on 548 
release properties; below the solubility limit, drug was homogeneously distributed and was non-549 
crystalline whereas exceeding the solubility generated crystalline domains in oil-in-oil generated 550 
materials with consequent burst release.  Thus, both the manufacturing method (which influences 551 
particle porosity and density) and drug:polymer compatibility and loading (which affect drug form 552 
and distribution) are responsible for burst release seen from our particles. 553 
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Figure legends 558 
Figure 1. Microscopic examination of hydrocortisone/ AQOAT® AS-MG films (at 10x magnification) at; 559 
(A) 0%, (B) 9%, (C) 10% and (d) 20% w/w theoretical loading.  560 
Figure 2. Scanning electron microscopy images of spray dried microparticles using Eudragit L100 with 561 
(A) 0% and (B) 10%, hydrocortisone loading and AQOAT-AS-MG with (C) 0% and (D) 2.5% drug 562 
loading. 563 
Figure 3. Scanning electron microphotographs of microparticles prepared by the oil in water 564 
emulsification solvent evaporation method; (A) , (B) and (C) show AQOAT AS-MG microparticles at 565 
0%, 2.5% and 25% hydrocortisone loading respectively. Image D and E shows 2.5% w/w 566 
hydrocortisone-loaded AQOAT microparticles at high magnification and drug-free Eudragit L100 567 
microparticles respectively.   568 
Figure 4. SEM photomicrographs of Eudragit L100 microparticles prepared from the oil-in-oil 569 
emulsification process at; (A) 0%, (B) 2.5%, (C) 10% and (D) 25% w/w theoretical hydrocortisone 570 
loading with respect to polymer. Images E and F show AQOAT AS-MG microparticles prepared at 0% 571 
and 2.5% hydrocortisone loading respectively.  572 
Figure 5. Stepped dissolution testing of prepared microparticles with pH change from 5 to 7 after 2 573 
hrs; (A) spray dried  Eudragit L100 microparticles at different hydrocortisone loadings, (B) Eudragit 574 
L100 microparticles prepared using the oil-in-oil microencapsulation method, (C) 2.5% 575 
hydrocortisone-loaded AQOAT AS-MG spray dried microparticles and (D) 2.5% hydrocortisone-576 
containing AQOAT AS-MG microparticles obtained from the oil-in-oil technique. HC denotes 577 
hydrocortisone. (mean±SD, n=3). 578 
Figure 6. DSC thermograms of Eudragit L100 powder, hydrocortisone, drug-free and hydrocortisone-579 
loaded Eudragit L100 microparticles produced from the spray drying and the oil in oil 580 
microencapsulation method. 581 
Figure 7. X-ray analysis of starting materials (hydrocortisone and Eudragit L100) and hydrocortisone-582 
loaded microparticles prepared from the oil-in-oil encapsulation method and spray drying. 583 
Figure 8. Raman spectra of hydrocortisone (black line) and Eudragit L100 (red line). 584 
Figure 9. Raman depth profiling (A) and scanning electron microscopy (B) showing the internal 585 
composition of 25% w/w hydrocortisone-loaded microparticles prepared from the oil-in-oil 586 
microencapsulation technique. (C), (D) and (E) represents the component analysis of hydrocortisone 587 
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(red line) and Eudragit L100 (blue line) within the oil-in-oil prepared microparticles as a function of 588 
depth. Depth profiling was performed from the surface (0 µm) to a depth of -15.2 µm for 2.5% (E) 589 
and 10% w/w (D) hydrocortisone-loaded microparticles and -38.0 µm for 25% w/w drug-containing 590 
microparticles (C). HC denotes hydrocortisone. 591 
Table legends 592 
Table 1. Yield, tap density and encapsulation efficiency values of Eudragit L100 and AQOAT AS-MG 593 
microparticles prepared from the spray drying method with variable hydrocortisone loadings. 594 
Table 2. Yield and encapsulation efficiency of hydrocortisone-loaded AQOAT AS-MG microparticles 595 
prepared from the oil-in-water emulsification process. 596 
Table 3. Yield, tap density and encapsulation efficiency values of Eudragit L100 and AQOAT AS-MG 597 
microparticles prepared from the oil in oil emulsification method at variable hydrocortisone 598 
loadings. 599 
Table 4. Residual solvent content (% w/w) of the microparticles (MPs) prepared from the oil-in-oil 600 
and spray drying methods. 601 
  602 
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Figure 1.. Microscopic examination of hydrocortisone/ AQOAT
®
 AS-MG films (at 10x magnification) at; (A) 0%, (B) 9%, (C) 603 
10% and (D) 20% w/w  theoretical loading.  604 
A B 
C D 
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Figure 2. Scanning electron microscopy images of spray dried microparticles using Eudragit L100 with (A) 0% and (B) 605 
10%, hydrocortisone loading and AQOAT-AS-MG with (C) 0% and (D) 2.5% drug loading. 606 
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Figure 3. Scanning electron microphotographs of microparticles prepared by the oil in water emulsification solvent 608 
evaporation method; (A) , (B) and (C) show AQOAT AS-MG microparticles at 0%, 2.5% and 25% hydrocortisone loading 609 
respectively. Image D and E shows 2.5% w/w hydrocortisone-loaded AQOAT microparticles at high magnification and 610 
drug-free Eudragit L100 microparticles respectively.  611 
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Figure 4. SEM photomicrographs of Eudragit L100 microparticles prepared from the oil-in-oil emulsification process at; 613 
(A) 0%, (B) 2.5%, (C) 10% and (D) 25% w/w theoretical hydrocortisone loading with respect to polymer. Images E and F 614 
show AQOAT AS-MG microparticles prepared at 0% and 2.5% hydrocortisone loading respectively.  615 
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Figure 5. Stepped dissolution testing of prepared microparticles with pH change from 5 to 7 after 2 hrs; (A)spray dried  617 
Eudragit L100 microparticles at different hydrocortisone loadings, (B) Eudragit L100 microparticles prepared using the 618 
oil-in-oil microencapsulation method, (C) 2.5% hydrocortisone-loaded AQOAT AS-MG spray dried microparticles and (D) 619 
2.5% hydrocortisone-containing AQOAT AS-MG microparticles obtained from the oil-in-oil technique. HC denotes 620 
hydrocortisone. (mean±SD, n=3). 621 
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 623 
Figure 6. DSC thermograms of Eudragit L100 powder, hydrocortisone, drug-free and hydrocortisone-loaded Eudragit L100 624 
microparticles produced from the spray drying and the oil in oil microencapsulation method. 625 
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 627 
Figure 7.  X-ray analysis of starting materials (hydrocortisone and Eudragit L100) and hydrocortisone-loaded 628 
microparticles prepared from the oil-in-oil encapsulation method and spray drying.  629 
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 632 
Figure 8. Raman spectra of hydrocortisone (black line) and Eudragit L100 (red line). 633 
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Figure 9. Raman depth profiling (A) and scanning electron microscopy (B) showing the internal composition of 25% w/w 635 
hydrocortisone-loaded microparticles prepared from the oil-in-oil microencapsulation technique. (C), (D) and (E) 636 
represents the component analysis of hydrocortisone (red line) and Eudragit L100 (blue line) within the oil-in-oil 637 
prepared microparticles as a function of depth. Depth profiling was performed from the surface (0 µm) to a depth of -638 
15.2 µm for 2.5% (E) and 10% w/w (D) hydrocortisone-loaded microparticles and -38.0 µm for 25% w/w drug-containing 639 
microparticles (C). HC denotes hydrocortisone. 640 
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Table 1. Yield, tap density and encapsulation efficiency values of Eudragit L100 and AQOAT AS-MG microparticles 642 
prepared by spray drying with variable hydrocortisone loadings. 643 
Polymer 
 
Drug loading  
(% w/w) 
Yield 
(%) 
Tap density 
(g/ml) 
Encapsulation 
Efficiency 
(%) 
Eudragit L100 0* 80.6 0.85±0.02 / 
Eudragit L100 2.5* 78.7 0.84±0.04 99.1±2.99 
Eudragit L100 10 47.7 0.92±0.03 88.6±3.63 
Eudragit L100 25* 67.6 1.02±0.01 94.6±1.00 
AQOAT AS-MG 0 53.1 0.57±0.03 / 
AQOAT AS-MG 2.5 72.7 0.59±0.04 98.9±0.92 
*Data from Rizi et al. (2010) shown for comparison. 644 
645 
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Table 2. Yield and encapsulation efficiency of hydrocortisone-loaded AQOAT AS-MG microparticles 646 
prepared from the oil-in-water emulsification process. 647 
Drug loading (% 
w/w) 
Yield (%) Tap density (g/ml) Encapsulation efficiency 
(%) 
0 88.0 0.31±0.01 NA 
2.5 63.2 0.25±0.02 23.35±1.09 
25 77.1 0.15±0.01 22.05±1.02 
648 
32 
 
Table 3. Yield, tap density and encapsulation efficiency values of Eudragit L100 and AQOAT AS-MG microparticles 649 
prepared from the oil-in-oil emulsification method at variable hydrocortisone loadings. 650 
Polymer Drug loading  
(% w/w) 
Yield 
(%) 
Tap density 
(g/ml) 
Encapsulation 
Efficiency 
(%) 
Eudragit L100 0 81.3 0.86±0.05 / 
Eudragit L100 2.5 89.5 1.03±0.01 94.84±1.79 
Eudragit L100 10 90.7 1.02±0.07 82.04±0.74 
Eudragit L100 25 86.0 0.33±0.02 73.62±2.38 
AQOAT AS-MG 0 86.7 0.66±0.03 / 
AQOAT AS-MG 2.5 90.7 0.86±0.04 100.9±2.9 
 651 
  652 
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Table 4. Residual solvent content (% w/w) of the microparticles (MPs) prepared from the oil-in-oil and spray drying 653 
methods. 654 
Hydrocortisone-loading  Spray dried MPs  Oil-in-oil MPs  
0%  6.97±0.38  7.74±0.06  
2.5%  7.33±1.08  7.64±0.10  
10%  7.41±0.56  7.59±0.14  
25%  6.59±0.79  7.80±0.38  
  655 
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